This story will be updated Oct. 26 to include detailed Sanovo trial results. | AstraZeneca has offered a detailed look at the ...
With ivonescimab’s first phase 3 win outside lung cancer and a $2 billion investment from AstraZeneca in its U.S. partner ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results